https://phescreening.blog.gov.uk/2017/01/31/deciding-how-best-to-roll-out-hpv-testing-as-the-primary-cervical-screening-test/

Deciding how best to roll out HPV testing as the primary cervical screening test

Evidence shows that human papillomavirus (HPV) testing is a better way of identifying women at risk of cervical cancer than the cytology (smear) test that examines cells under a microscope.

Last year, after reviewing the evidence, the UK NSC recommended that the HPV test should replace cytology as the first stage in cervical screening.

This will be a major change for the NHS Cervical Screening Programme (NHSCSP). An HPV primary screening implementation group of PHE Screening and NHS England experts is developing plans for how to roll out HPV primary screening nationally in England.

On 10 January 2017 the implementation group hosted an options appraisal meeting to consider the possible models for implementing HPV primary screening across England.

The Royal College of Pathologists, the British Association for Cytopathology and the Institute of Biomedical Science supported and informed this group. Dr Karin Denton, Regional Head of the Screening Quality Assurance Service, led the options appraisal meeting and it was facilitated by Costello Consulting. Many thanks to everyone for their time and support with this piece of work.

The options appraisal considered 10 important objectives for each model (see diagram below).

Diagram showing 10 objectives considered and weighted by options appraisal

The options appraisal group previously met before Christmas to discuss and agree the relative importance of each of these 10 areas with stakeholders and agree how they should be weighted. The results of this discussion can be seen in the table below.

Quality and safety was weighted most important, reflecting the aim of screening to prevent as many cervical cancers as possible and maintain the highest standards.

Staffing capacity and maintaining a resilient service were also weighted highly along with effective IT connectivity and cost of safe delivery.

Objective Weight
Quality 18
Staffing feasibility 15
Effective IT connectivity 15
Cost of safe delivery 15
Linkage to local services 10
Delivery during transition 6
Adequate clinical support 6
Service sustainability 6
Specimen transport feasibility 5
Commissioning feasibility 4
Total 100

The options appraisal group considered 6 options in total.

  1. Many providers delivering HPV testing and cytology testing (aligns with current cervical screening model).

Diagram showing option 1

  1. Centralisation of HPV testing with cytology testing from existing providers.
    Diagram showing option 2
  2. Centralisation of cytology testing with HPV testing by many, mainly local, providers.
    Diagram showing option 3
  3. Centralisation of HPV testing and cytology testing as a single seamless service, using:
    • a minimum number of 4 to 5 centralised services performing both HPV testing and cytology screening (option 4a)

Diagram showing option 4a

  • a maximum number of 10 to 15 centralised services performing both HPV testing and cytology screening (option 4b)
    diagram showing option 4b
  1. A network approach of many providers of HPV and cytology screening.

diagram showing option 5

Recommendations

After evaluating and scoring each of the proposed option models, the options appraisal group identified centralisation of HPV testing and cytology testing as a single, seamless service as the recommended model of delivery. 

Options 4b (using a maximum number of 10 to 15 centralised services) and option 4a (using a minimum of 4 to 5 centralised services) both scored highly in terms of quality and safety. These were the only options to score ‘above the line’ for acceptability, achieving a total weighted score of more than 1,000 points (50% of the maximum score possible). See table below.

Table showing how the weighted scores of each option after the appraisal

Next steps

NHS England, as commissioners of cervical screening, will now take forward work to make sure that the preferred options are deliverable.

This work will include assessing costs, procurement arrangements, due diligence, the implication of each option on existing services and appropriate sign-off processes. Timescales for this work will be shared once available.

Janet’s new role

I’m pleased to be able to announce that Janet Rimmer has been appointed senior implementation lead for HPV primary screening.

Janet has extensive experience of working in cervical screening and will work with the NHSCSP team to take forward this work.

PHE Screening blogs

PHE Screening BLOGs provide up to date news from all NHS screening programmes – replacing our previously published newsletters.

You can register to receive updates direct to your inbox, so there’s no need to keep checking for new blogs.

17 comments

  1. Phil Bullock

    These factors on the face of it look to be those of greatest significance and weighted appropriately. But can I ask please...when costs are considered is that just the cost of laboratory testing or does it include sample taking and colposcopy referral costs? There are likely to be significant variances in these costs dependant on the chosen HPV testing technology - a cheaper HPV test may not be the most cost effective for the programme if a higher number of repeat tests and/or colposcopy referrals follow.

    Link to this comment Reply
  2. Phil Bullock

    PS Its also rather surprising to see that a history of robust service delivery does not feature as a parameter for assessment.

    Link to this comment Reply
    • Ruth Stubbs

      Dear Mr Bullock
      Thank you for your comment. Please note the objectives related to ‘cost of safe delivery’ not to ‘costs’ alone. Estimates of comparative costings of the different service configuration options were considered. We did not consider any issues of test platform selection as this does not impact on service configuration. We are pleased to assure you that these objectives were fully informed and supported by clinicians representing the professional bodies mentioned in the blog.
      Kind regards
      Ruth Stubbs

      Link to this comment Reply
  3. Irene Stratton

    It's an exciting opportunity for education about the risk factors for cervical cancer. I worked in the unit where much of the work was done in the 1980s about the role of viruses and the increase in risk with increasing number of sexual partners and in those who had sexual relationships at younger ages. When I first started work there it was thought that cervical cancer might be linked to smoking and sunbathing! By the time women enter the screening programme of course it may be too late for them to consider a change in behaviour or use of barrier contraception but they might be able to talk to their daughters, sisters and younger friends.
    So will PHE be explaining why the change in screening method is happening?

    Link to this comment Reply
  4. Karen Snelgrove

    How do you envisage colposcopy MDT meetings to factor in these proposed arrangements?

    Link to this comment Reply
    • Ruth Stubbs

      Thank you for your comments. The NHS Cervical Screening Programme standards and guidance are being reviewed and updated to ensure they will meet the requirements of HPV primary screening. Detail of the MDTs will be included in programme guidance and the service specification for the cervical screening. It is agreed that MDTs will need to continue to be run in a way which is accessible to colposcopy, cytology and histology but the way the meetings are delivered and which staff attend may change.

      Link to this comment Reply
  5. worried screener

    Does NHS England have a redundancy package to help pay for the inevitable job losses if option 4a is selected?

    Link to this comment Reply
    • Ruth Stubbs

      Thank you for your comment. Unfortunately Public Health England cannot advise on this aspect of the HPV Primary Screening implementation as it is in the remit of NHS England. NHS England will consider the impact of the recommendations from the options appraisal on the sustainability and transformation plans.

      Link to this comment Reply
  6. Callum

    Thank you for the blog which gives some clarity on laboratory configuration.
    As Hospital Based Programme Coordinator I have responsibility across cytology, colposcopy and histology and regardless of cytology configuration need to plan delivery of the colposcopy and histology service.
    You must by now have data from the pilot sites covering the first three years of HPV primary screening. Please could you tell me, for each of the first three years, the percentage increase or decrease in colposcopy referrals and biopsy/LLETZ specimens.
    Alternatively if this information is in the public domain , where can I find it?

    Link to this comment Reply
    • Ruth Stubbs

      Thank you for your comment on the blog post. I am pleased you found it helpful. The data from the HPV pilot sites is still in draft and has not yet been published. We have asked for the timescales for data publication and hope that it is not too far away.

      Link to this comment Reply
  7. Concerned Cytologist

    Will NHS England consider the current location of essential staff required to deliver the reconfigured service to ensure the location of the new provider laboratories are within reasonable distances? Previous experience has shown that if this is not considered, the staff required to deliver the service will not transfer and the new provider will be unable to deliver due to insufficient staff. This is particularly relevant for Option 4a.

    Link to this comment Reply
    • Ruth Stubbs

      Thank you for your comment.
      As this question relates to NHS England, PHE is not in a position to comment. NHS England is currently considering the next steps from the options appraisal recommendations. These include:
      • working closely with the national procurement team to understand what procurement arrangements would need to be put in place for each option and the timescales for this
      • liaising with the local commissioning teams to understand the cost implications if either option was to be implemented and to undertake financial modelling
      • working with other national teams (such as primary care services) to understand the impact that either option would have on current service delivery
      • ensuring that both options have been considered in a wider context, including the impact on the s7a agreement and also the sustainability and transformation plan agenda

      Link to this comment Reply
  8. katrehman

    I don't work in health care but I did get made redundant 3 years ago when my employer went bust so understand its a horrible thing to happen however here we are talking about health care and the move to HPV testing which is supposed to benefit women. There fore surely that's the most important factor..to improve womens health! I'm personally not a fan of the cervical screening programme and also feel if less money was wasted on campaigns designed to scare us into screening. .if less was spent chasing women who choose not to screen...there might be more money available to fund new jobs elsewhere and also fund the self testing option the Dutch have had since the beginning of last year. Surely you MUST see that women aren't being swayed by these scare campaigns and LOATHE this outdated test??

    Link to this comment Reply
    • Ruth Stubbs

      Thank you for sharing your opinions. The NHS Cervical Screening Programme is currently considering self-testing options which will become a possibility once HPV primary screening has been implemented.

      Link to this comment Reply
  9. Liz Lewis

    Is it absolute that all cervical changes are from HPV, my understanding that it is high percentage but not 100% if so what of those few who are HPV clear.

    Link to this comment Reply
    • Ruth Stubbs

      Thank you for your comments and question. Evidence shows that 99.7% of cervical cancers contain high risk (HR) HPV DNA. Looking at cases of cervical intraepithelial neoplasia (CIN), the higher the grade of CIN, the more frequently HR-HPV is found. This suggests that women who do not have HR-HPV are extremely unlikely to develop cervical cancer in the short to medium term.

      Link to this comment Reply

Leave a comment